FORM PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

TCA-13144 Attorney Docket No.:

Serial No.: 10/578,943

Applicant: Soo-Hyun Kim et al.

Group Art Unit: 1647

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Filing or 371(c) Date: 11/09/2006

				U.S. PATENT DOCUMENTS		··· ·			
Examiner	Cite	Document /	Publication /		Class	Subclass	Filin	g Date	
Initials	No.	Patent Number	Issue Date	Applicant / Patentee					
OIPE	1	6,277,969	08/21/2001	Le et al.	536	23.1		2/1998	
	2 2 3	6,448,380	09/10/2002	Rathjen et al.	530	388.23		3/2000	
MAR 0 7 2008		6,572,852	06/03/2003	Smith et al.	424	85.2	10/12/2001		
	<i>yy</i> /4	6,605,280	08/12/2003	Novick et al.	424	184.1			
\$ 000 mak	5	6,706,491	03/16/2004	Chang et al.	435	29		9/1999	
PAODAART	6	6,989,262	01/24/2006	Bejanin et al.	435	226	11/13/2001		
	7	2003/0087270	05/08/2003	Schlegel et al.	435	6	06/12/2002		
	8	2003/0092616	05/15/2003	Matsuda et al.	514	12	05/24/2002		
	9	2003/0148316	08/07/2003	Lipford et al.	435	6	08/01/2002		
	10	2003/0154032	08/14/2003	Pittman et al.	702	20	12/17	7/2001	
	l I I	2005/0048490	03/03/2005	Azimzai et al.	435	6	ļ	5/2002	
	12	2005/0130145	06/16/2005	Yue et al.	· 435	6	10/03	3/2002	
	13	2005/0208496	09/22/2005	Ohtani et al.	435	6	07/31	1/2003	
	14	2006/0088532	04/27/2006	Alitalo et al.	424	145.1	03/07	7/2003	
							<u></u>		
		F	OREIGN PATENTS	OR PUBLISHED FOREIGN PATENT APPLICA	ATIONS				
		Document				Translat	slation		
		Number	Publication Date	Country / Patent Office	Class	Subclass	Yes	No	
	15	WO 01/064886	09/07/2001	WIPO					
	16	WO 02/059260	08/01/2002	WIPO					
	17	WO 02/083898	10/24/2002	WIPO					
	18	WO 02/096943	12/05/2002	WIPO			Х	ĺ	
	19	WO 03/080640	10/02/2003	WIPO					
	20	WO 2005/016962	02/24/2005	WIPO					
	21	WO 2006/071088	07/06/2006	WIPO					
	22	EP 1487857	12/22/2004	EPO					
		OTHER	DOCUMENTS (Incl	uding Author, Title, Date, Relevant Pages, Place	of Publication)				
	23	Banda et al.," Mech	anisms of effects of co	omplement inhibition in murine collagen-induced	arthritis," Arthrit	is Rheum, 46:30	65, 2002		
	24	Banda et al., "Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein," J Immunol, 170:2100-2105, 2003							
	25	Bendele et al., "Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis," Arthritis Rheum, 43:2648-2659, 2000							
	26	Bernot et al., "A trai	Bernot et al., "A transcriptional map of the FMF region" Genomics, 50:147-160, 1998						
	27	+	Cohen, "Systemic Autoimmunity," in Paul (ed.) <u>Fundamental Immunology</u> , Lippincott-Raven Publishers: Philadelphia, pp. 1067-1088, 1999						
	28	Dahl et al., "Identification of a novel gene expressed in activated natural killer cells and T cells," J Immunol, 148:597-603, 1992							
	29	Davis et al., "Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type 1: a clinical update," Ann Rhem Dis, 59Suppl1:i41-3, 2000							
	30	Faggioni et al., "IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice," J Immunol, 167:5913-5920, 2001							
	31	 	Firestein, "Rheumatoid Arthritis," in Scientific American Medicine, 2000						

Examiner:

Date Considered:

FORM PTO-1449 (Modified)

U.S. Jepartment of Commerce Patent and Trademark Office

Attorney Docket No. 1CA-13144

Serial No.: 10/578,943

Applicant: Soo-Hyun Kim et al.

Group Art Unit: 1647

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Filing or 371(c) Date: 11/09/2006

(3) 0111 3 113		
	32	Panelli et al., "Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration" Genome Biol, 3(7):research0035.1-0035.17, 2002
	33	Gracie et al., "A proinflammatory role for IL-18 in rheumatoid arthritis," J Clin Invest, 104:1393-1401, 1999
	34	Steed et al., "Inactivation of TNF signaling by rationally designed dominant-negative TNF variants," Science, 301:1895-1898, 2003
	35	GenBank Accession No. AAH09401 GI:14424787 (2002)
	36	GenBank Accession No. AAH18782 GI:17511868 (2002)
	37	GenBank Accession No. AAS80144 GI:46095218 (2005)
	38	Dinarello and Kim, "IL-32, a novel cytokine with a possible role in disease," Ann Rheum Dis, 65(Suppl III):iii61-iii64, 2006
	39	Joosten et al., "IL-32, a proinflammatory cytokine in rheumatoid arthritis," Proc Natl Acad Sci USA, 103:3298-3303, 2006
	40	Kim et al., "Interleukin-32: A cytokine and inducer of TNFα," Immunity, 22:131-142, 2005
	41	Neto et al., "Shotgun sequencing of the human transcriptome with ORF expressed sequence tags," Proc Natl Acad Sci USA, 97:3491-3496, 2000
	42	Plater-Zyberk et al., "Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis," J Clin Invest, 108:1825-1832, 2001
	43	Strausberg et al., "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequence," Proc Natl Acad Sci USA, 99:16899-16903, 2002
	4	
:		
	ĺ	
-		
	٠	

Examiner:

Date Considered: